Strides Pharma gets USFDA nod to market HIV drug
Strides Pharma Science said its subsidiary has received approval from the US health regulator to market a generic version of Gilead Sciences' Atripla tablets which are indicated to help control HIV infection.
Strides Pharma Science on Wednesday said its subsidiary has received approval from the US health regulator to market a generic version of Gilead Sciences' Atripla tablets which are indicated to help control HIV infection.
Singapore-based Strides Pharma Global, a stepdown wholly-owned subsidiary of the company, has received approval for Efavirenz (600mg), Emtricitabine (200mg), Tenofovir Disproxil Fumurate (300mg), (EET) tablets from the US Food & Drug Administration (USFDA), the drug firm said in a statement.
The company's product is bioequivalent and therapeutically equivalent to Atripla Tablets of Gilead Sciences LLC, it added.
As per per IQVIA, Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumurate tablet (EET) has a market opportunity of USD 7.5 million in the US.
Shares of Strides Pharma Science ended 2.51 per cent up at Rs 508.20 apiece on the BSE on Wednesday.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Power of Compounding: How many years will it take to reach Rs 3 crore corpus if your monthly SIP is Rs 4,000, Rs 5,000, or Rs 6,000
Power of Compounding: Salary Rs 25,000 per month; is it possible to create over Rs 2.60 crore corpus; understand it through calculations
Reduce Home Loan EMI vs Reduce Tenure: Rs 75 lakh, 25-year loan; which option can save Rs 25 lakh and 64 months and how? Know here
Top 7 Large and Mid Cap Mutual Funds with Best SIP Returns in 5 Years: No. 1 fund has turned Rs 15,000 monthly SIP investment into Rs 20,54,384; know about others
New Year Pick by Anil Singhvi: This smallcap stock can offer up to 75% return in long term - Check targets
05:39 PM IST